132 related articles for article (PubMed ID: 9168435)
1. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias.
Perentesis JP; Bendel AE; Shao Y; Warman B; Davies SM; Yang CH; Chandan-Langlie M; Waddick KG; Uckun FM
Leuk Lymphoma; 1997 Apr; 25(3-4):247-56. PubMed ID: 9168435
[TBL] [Abstract][Full Text] [Related]
2. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
[TBL] [Abstract][Full Text] [Related]
3. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
Williams MD; Rostovtsev A; Narla RK; Uckun FM
Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
[TBL] [Abstract][Full Text] [Related]
5. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
[TBL] [Abstract][Full Text] [Related]
6. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
[TBL] [Abstract][Full Text] [Related]
7. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein.
Hogge DE; Willman CL; Kreitman RJ; Berger M; Hall PD; Kopecky KJ; McLain C; Tagge EP; Eaves CJ; Frankel AE
Blood; 1998 Jul; 92(2):589-95. PubMed ID: 9657759
[TBL] [Abstract][Full Text] [Related]
8. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
[TBL] [Abstract][Full Text] [Related]
9. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells.
Burbage C; Tagge EP; Harris B; Hall P; Fu T; Willingham MC; Frankel AE
Leuk Res; 1997 Jul; 21(7):681-90. PubMed ID: 9301690
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
Frankel AE; Hall PD; Burbage C; Vesely J; Willingham M; Bhalla K; Kreitman RJ
Blood; 1997 Nov; 90(9):3654-61. PubMed ID: 9345050
[TBL] [Abstract][Full Text] [Related]
11. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
Feuring-Buske M; Frankel A; Gerhard B; Hogge D
Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
13. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.
Terpstra W; Rozemuller H; Breems DA; Rombouts EJ; Prins A; FitzGerald DJ; Kreitman RJ; Wielenga JJ; Ploemacher RE; Löwenberg B; Hagenbeek A; Martens AC
Blood; 1997 Nov; 90(9):3735-42. PubMed ID: 9345060
[TBL] [Abstract][Full Text] [Related]
14. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
15. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
[TBL] [Abstract][Full Text] [Related]
16. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
Hall PD; Willingham MC; Kreitman RJ; Frankel AE
Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
[TBL] [Abstract][Full Text] [Related]
17. Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor.
Shao Y; Warman BE; Perentesis JP
Methods Mol Biol; 2001; 166():31-53. PubMed ID: 11217375
[No Abstract] [Full Text] [Related]
18. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins.
Jedema I; Barge RM; Frankel AE; Willemze R; Falkenburg JH
Exp Hematol; 2004 Feb; 32(2):188-94. PubMed ID: 15102480
[TBL] [Abstract][Full Text] [Related]
19. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Horita H; Frankel AE; Thorburn A
Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
[No Abstract] [Full Text] [Related]
20. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
